Clinical Trials in Siping, China
12 recruiting
Showing 1–15 of 15 trials
Recruiting
Phase 3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
ObesityHeart Failure With Preserved Ejection FractionHeart Failure With Mildly Reduced Ejection Fraction
Amgen5,056 enrolled603 locationsNCT07037459
Recruiting
Phase 3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Cardiovascular DiseasesHypertensionDiabetes Mellitus, Type 2
Boehringer Ingelheim11,800 enrolled1152 locationsNCT07064473
Recruiting
Phase 4
A Study Testing How Well the Drug Extract of Ginkgo Biloba Leaves Tablets Works for People With Memory or Thinking Problems After a Stroke When Added to Standard Treatment
Ischemic Stroke HospitalizedImpairment, Cognitive
Dr. Willmar Schwabe GmbH & Co. KG400 enrolled30 locationsNCT07220538
Recruiting
Phase 3
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
Hypertension
Eli Lilly and Company974 enrolled100 locationsNCT06948422
Recruiting
Phase 2Phase 3
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia
Dyslipidaemia
AstraZeneca360 enrolled43 locationsNCT06834932
Recruiting
Phase 3
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
Atherosclerotic Cardiovascular Disease (ASCVD)Elevated Lp(a)
Eli Lilly and Company10,450 enrolled751 locationsNCT07157774
Recruiting
Phase 3
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
Hypertension
Eli Lilly and Company487 enrolled99 locationsNCT06952530
Recruiting
Phase 3
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
HypertensionOverweight or Obesity
Eli Lilly and Company487 enrolled99 locationsNCT06948435
Recruiting
Phase 3
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
Cardiovascular Disease
AstraZeneca15,100 enrolled1264 locationsNCT07000357
Recruiting
Phase 3
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
Heart Failure
AstraZeneca11,300 enrolled928 locationsNCT06677060
Recruiting
Phase 3
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
Heart Failure
Novo Nordisk A/S5,600 enrolled1117 locationsNCT05636176
Recruiting
Not Applicable
TrIal of Early Minimally Invasive Catheter Evacuation With Thrombolysis in IntraCerebral Hemorrhage
Intracerebral Hemorrhage
Xuanwu Hospital, Beijing750 enrolled50 locationsNCT07187687
Recruiting
Phase 2
A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder
Pulmonary Disease, Chronic Obstructive
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.195 enrolled29 locationsNCT07252908
Recruiting
Phase 3
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
COPD, Chronic Obstructive Pulmonary Disease
AstraZeneca5,000 enrolled917 locationsNCT06283966
Recruiting
Phase 3
Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder
Insomnia Disorder
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.1,041 enrolled88 locationsNCT05525637